ENVVENO MEDICAL CORP

Company Overview

enVVeno Medical Corporation is a late clinical-stage medical device company developing bioprosthetic replacement venous valves to treat severe chronic venous insufficiency, with its lead implantable product VenoValve in a pivotal U.S. trial (SAVVE, 75 patients) and a submitted PMA module in late 2024. The company is pre-revenue, operates an integrated R&D and cGMP-capable manufacturing facility in Irvine, CA, holds a portfolio of tissue-processing and preservation patents, and is highly milestone-driven — clinical readouts, IDE/PMA outcomes and supply-chain continuity determine commercialization timing. enVVeno’s small team (37 FTEs) and limited operating history mean cash runway, clinical progress, and regulatory timelines dominate near-term performance and capital needs.

Executive Compensation Practices

Given the firm’s pre-revenue, milestone-dependent model, executive pay is likely weighted toward equity and milestone-based long-term incentives rather than cash salary: regulatory submissions, trial enrollment/completion, favorable safety/efficacy readouts, IP development and successful fundraising are natural performance triggers. The filings show stock‑based compensation materially affects SG&A (lower in 2024 as SAVVE enrollment completed, then rising in H1 2025 with commercialization hiring and one‑time charges), indicating variability in equity awards and occasional retention/severance payouts. For a small, late-stage device firm, compensation packages typically include options/RSUs, performance-based bonuses tied to FDA milestones and commercialization readiness, and occasional retention awards to secure key technical and regulatory personnel.

Insider Trading Considerations

Insider trading at enVVeno should be monitored with heightened scrutiny because the company is pre-revenue with concentrated insider ownership, limited float and event-driven price sensitivity — a few insider transactions can materially move the stock. Expect blackout windows and the use of Rule 10b5‑1 plans around material events (PMA/IDE submissions, pivotal data releases, FDA decisions) and preclearance requirements given frequent material non‑public information; filings under Section 16 (Form 4) will be important to track timely. Also watch for insider option exercises and sales tied to liquidity needs (small cash runway and upcoming financing) which can coincide with dilutive financings and may be interpreted by the market as signaling; regulatory QSR/recall risks and Breakthrough Device communications can also create short, high‑impact trading windows.